Alternative chromatographic processes for no-carrier added 177Lu radioisotope separation

So, Le Van; Morcos, N.; Zaw, Myo Myint; Pellegrini, Paul A.; Greguric, Ivan

doi:10.1007/s10967-007-7129-8

Cited by 27 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main advantages of this method are the low levels of 177m Lu produced and the high specific activity. Although challenging, many have demonstrated separation to yield nca 177 Lu. − For example, small-scale reversed-phase ion pair chromatography has led to 177 Lu with high radionuclidic purity and an 84% yield. The dissolved Yb 2 O 3 target (5 mg) was loaded onto a reverse-phase column and 177 Lu eluted with 0.25 M α-HIBA/0.1 M octanesulfonate .…”

Section: Lutetiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract

Section: Lutetiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…New or improved methods to effect such separations have been reported for samarium-153, 60 terbium-161, 61 and lutetium-177. [62][63][64] Other routes to lutetium-177 have been proposed 65 using the proton irradiation of hafnium or tantalum.…”

Section: Isotope Productionmentioning

confidence: 99%

Radiochemistry

Urch¹

2009

Annu. Rep. Prog. Chem., Sect. A: Inorg. Chem.

View full text Add to dashboard Cite

“…Precipitation of lutetium hydroxide by addition of NaOH and re-dissolution of the hydroxide with 0.1 mol L -1 HCl delivered a 177 LuCl 3 solution with high radionuclide purity (>99.9%) for further processing of the radiopharmaceutical. An alternative chromatographic process was presented by Le Van So et al [182,183]. A conventional multi-column solid phase extraction chromatography, with HDEHP impregnated on an OASIS-HLB sorbent (OASIS-HDEHP), was used to separate the non-carrier added 177 Lu from the bulk quantity of ytterbium target.…”

mentioning

confidence: 99%

“…This separation technique exploits the large variation of Ln 3+ distribution ratios in different acidity HCl solution -OASIS-HDEHP resin systems for consecutive loading-eluting cycles performed on different columns. Le Van So et al described the use of this separation system in a multi-column chromatographic process and a conventional column chromatographic separation combined with HPLC [182,183]. The final non-carrier added 177 LuCl 3 product was obtained after evaporation to dryness and reconstituting the residue in 0.05 mol L -1 HCl.…”

mentioning

confidence: 99%